Bio-Rad Laboratories Inc

Healthcare · Medical Devices

387.50$ +2.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Bio-Rad Laboratories Inc (BIO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 651 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement BIO
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	509	571	500	505	535	620	552	576	545	617	554	573	561	624	572	537	647	790	727	716	747	733	700	691	681	730	677	681	632	681	611	638	650	667	585	652	653	693	592	651	2,589
Cost of Revenue	229	257	230	231	230	281	249	274	258	284	242	265	254	294	254	244	280	330	326	314	310	332	297	295	307	333	314	319	296	315	284	283	294	326	279	306	310	348	283	305	1,246
Gross Profit	279	314	270	273	305	340	302	302	287	333	312	308	307	330	317	293	367	460	401	402	437	401	403	396	374	397	362	362	336	366	326	355	356	342	306	345	343	345	309	346	1,344
Research & Development	50	58	49	63	61	77	49	47	49	53	48	50	48	57	49	52	60	66	74	63	64	70	60	67	70	66	75	65	44	62	64	59	91	80	74	61	71	66	63	61	261
Selling, General & Administrative	201	220	195	213	197	204	209	210	201	214	208	201	202	214	194	189	198	194	226	213	212	224	198	209	206	210	226	208	201	207	215	195	200	204	209	208	207	221	212	212	852
Total Operating Expenses	251	278	244	276	258	281	259	258	250	267	255	251	250	271	243	241	258	285	300	277	281	294	256	276	281	278	301	273	245	268	274	254	291	284	282	268	278	282	275	273	1,109
Operating Income	28	-23	26	-2.4	46	59	44	44	36	65	57	56	57	59	74	52	110	175	101	125	157	107	146	120	93	119	62	90	91	98	52	101	64	58	24	77	66	62	34	73	235
Interest Expense	5.6	5.1	5.3	6.0	5.9	5.5	5.8	6.0	6.1	6.1	6.0	5.8	5.5	6.1	5.7	5.7	5.7	4.7	0.4	0.4	0.4	0.4	4.0	11	12	12	12	12	12	12	12	12	12	12	12	13	12	12	12	12	49
Pre-Tax Income	23	-28	20	1.1	39	38	864	340	350	-1,041	1,127	770	-335	699	899	1,246	1,684	1,079	1,297	1,157	5,022	-2,038	-4,368	-1,223	-209	1,091	85	-1,500	137	428	491	-2,786	862	-909	83	414	-431	929	-690	542	350
Income Tax Expense	4.3	-7.6	7.7	-3.9	11	-40	207	72	81	-213	262	171	-76	146	213	280	370	239	320	243	1,094	-464	-1,001	-296	-45	264	16	-338	31	79	107	-621	208	-193	19	96	-89	209	-163	171	128
Net Income	18	-21	12	5.0	27	77	657	268	269	-829	865	599	-259	553	686	966	1,315	839	977	914	3,928	-1,574	-3,367	-927	-164	833	69	-1,162	106	350	384	-2,165	653	-716	64	318	-342	720	-527	371	222
EBITDA	67	9.7	59	44	80	101	904	380	391	100	1,176	818	-285	709	938	1,286	1,724	1,119	1,340	1,201	5,066	-2,004	-4,331	-1,170	-161	1,153	143	-1,430	198	494	551	-2,727	923	-847	134	477	-365	994	-637	542	535

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings